Certara (700) Stock Overview
Provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 700 from our risk checks.
700 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.14 |
| 52 Week High | US$11.63 |
| 52 Week Low | US$4.45 |
| Beta | 1.62 |
| 1 Month Change | -5.03% |
| 3 Month Change | -35.54% |
| 1 Year Change | n/a |
| 3 Year Change | -76.42% |
| 5 Year Change | -79.76% |
| Change since IPO | -77.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 700 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 6.8% | -0.6% | 3.7% |
| 1Y | n/a | 17.1% | 11.2% |
Return vs Industry: Insufficient data to determine how 700 performed against the German Healthcare Services industry.
Return vs Market: Insufficient data to determine how 700 performed against the German Market.
Price Volatility
| 700 volatility | |
|---|---|
| 700 Average Weekly Movement | 7.7% |
| Healthcare Services Industry Average Movement | 5.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 700 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 700's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,546 | Jon Resnick | www.certara.com |
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
Certara, Inc. Fundamentals Summary
| 700 fundamental statistics | |
|---|---|
| Market cap | €810.44m |
| Earnings (TTM) | -€1.36m |
| Revenue (TTM) | €355.93m |
Is 700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 700 income statement (TTM) | |
|---|---|
| Revenue | US$418.84m |
| Cost of Revenue | US$161.13m |
| Gross Profit | US$257.71m |
| Other Expenses | US$259.31m |
| Earnings | -US$1.59m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 11, 2026
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 61.53% |
| Net Profit Margin | -0.38% |
| Debt/Equity Ratio | 27.8% |
How did 700 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 12:45 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Certara, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Vruwink | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |